Associated Genetic Biomarkers
Signal transducer and activator of transcription 4 (STAT4) is a gene that encodes a transcription factor protein that mediates responses to IL12 in lymphocytes and regulates the differentiation of helper T-cells. Missense mutations, nonsense mutations, silent mutations, frameshift deletions, and in-frame deletions are observed in cancers such as endometrial cancer, intestinal cancer, and skin cancer.
STAT4 is altered in 1.72% of all cancers with cutaneous melanoma, colon adenocarcinoma, melanoma, conventional glioblastoma multiforme, and lung adenocarcinoma having the greatest prevalence of alterations .
The most common alterations in STAT4 are STAT4 Mutation (1.59%), STAT4 Amplification (0.20%), STAT4 R400* (0.20%), STAT4 R705Q (0.09%), and STAT4 D256N (0.14%) .
STAT4 status serves as an inclusion eligibility criteria in 1 clinical trial, of which 0 are open and 1 is closed. Of the trial that contains STAT4 status as an inclusion criterion, 1 is phase 2 (0 open).
Trials with STAT4 status in the inclusion eligibility criteria most commonly target malignant solid tumor .
The most frequent alteration to serve as an inclusion eligibility criterion is STAT4 Mutation .
Irinotecan and sorafenib are the most frequent therapies in trials with STAT4 as an inclusion criteria .
Significance of STAT4 in Diseases
Malignant Solid Tumor +
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.